Major Article

High rate of detection of OXA-23-producing Acinetobacter from two general hospitals in Brazil

Elaini Aparecida de Oliveira[1], Geraldo Renato de Paula[2], Pedro Jose Juan Mondino[3], Thiago Pavoni Gomes Chagas[3], Silvia Susana Bona de Mondino[1] and Cláudia Rezende Vieira de Mendonça-Souza[1]

[1]. Universidade Federal Fluminense, Faculdade de Medicina, Pós-graduação em Patologia, Niterói, RJ, Brasil.
[2]. Universidade Federal Fluminense, Faculdade de Farmácia, Pós-graduação em Ciências Aplicadas a Produtos para a Saúde, Niterói, RJ, Brasil.
[3]. Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Patologia, Niterói, RJ, Brasil.

Abstract

Introduction: In recent decades, the prevalence of carbapenem-resistant Acinetobacter isolates has increased, and the production of oxacillinase (OXA)-type carbapenemases is the main mechanism underlying resistance. We evaluated OXA production from 114 Acinetobacter isolates collected between March and December 2013 from different clinical specimens of patients in two hospitals (Hospital 1 [n = 61] and Hospital 2 [n = 53]) located in Niterói, Rio de Janeiro, Brazil. We also evaluated the genetic diversity of OXA-producing isolates.

Methods: All the isolates were identified through the automated system Vitek II and matrix-assisted laser desorption ionization-time of flight mass spectrometry MALDI-TOF MS as belonging to the A. baumannii-A. calcoaceticus complex. Antimicrobial susceptibility profiles were verified through agar diffusion tests. The presence of OXA-encoding genes was confirmed by PCR. The genetic diversity of isolates positive for carbapenemase production was analyzed through pulsed-field gel electrophoresis.

Results: There was a high rate of resistance to carbapenems in the isolates (imipenem: 96%; meropenem: 92%) from both hospitals. Moreover, a high percentage (95.6%) of OXA-23-positive isolates was observed for both hospitals, indicating that this was the main mechanism of carbapenem-resistance among the studied population. In addition, most isolates (96.5%) were positive for blaOXA-51. A high genetic diversity and a few major genotypes were found among the OXA-23-positive isolates analyzed. Only intra-hospital dissemination was observed.

Conclusions: The elevated dissemination of blaOXA-23-like observed among Acinetobacter isolates from both the studied hospitals highlights the need for continuous epidemiological surveillance in these institutions.

Keywords: Acinetobacter spp. Carbapenem-resistance. OXA-23.

INTRODUCTION

A. baumannii-A. calcoaceticus complex includes opportunistic pathogens affecting severely ill patients. The choice of treatment for serious infections caused by Acinetobacter is frequently based on the use of carbapenems1. However, carbapenem resistance among clinical isolates of Acinetobacter spp. has been reported worldwide. In addition, these isolates may have concomitant resistance to most conventional antimicrobial agents and cause difficulty in treating infections, and leave few treatment options2.

Different mechanisms can confer resistance to carbapenems in Acinetobacter, such as decreased permeability of the outer membrane, increased expression of efflux pumps, changes in the affinity of penicillin-binding proteins, and the production of carbapenemases. Among them, the production of carbapenemases, such as more frequent Class D beta-lactamases, also called oxacillinases (OXAs), less frequent Class B, also known as metallo-beta-lactamases (including IMP, VIM, SIM, and NDM-1 types) and Class A (of KPC or GES type) is the most important carbapenem resistance mechanism3-5.

The main groups of OXA-type carbapenemases identified in A. baumannii are OXA-23-like, OXA-24/40-like, OXA-58-like, OXA-143-like, and OXA-235-like groups and are composed
of acquired enzymes and OXA-51-like group, which encodes a chromosomal intrinsic OXA in A. baumannii. This intrinsic OXA may be super-expressed and associated with carbapenem resistance6,7. In Brazil, carbapenem-resistant Acinetobacter usually produce OXA-23, followed by OXA-14310.

Thus, we aimed to characterize carbapenem-resistant Acinetobacter isolates obtained from two health institutions located in the city of Niterói, Rio de Janeiro State, Brazil, evaluated the production of OXAs, and determined their genetic relationship.

METHODS

Bacterial Isolates

One hundred and fourteen Acinetobacter isolates were obtained from patients at two general hospitals located in Niterói; Hospital 1 (a 290-bed public university teaching hospital; n = 61) and Hospital 2 (a 201-bed tertiary private hospital; n = 53) from March to December 2013.

The most frequent sites for the collection of these specimens were the lower respiratory tract containing secretions (48; 42.1%) such as tracheal aspirate (40; 83.3%), bronchoalveolar lavage (6; 12.5%), sputum and pleural fluid (1 each; 2.1% each), the blood (23; 20.2%), the urine (12; 10.5%), and catheter tip (9; 7.9%). Other sources represented 11.4% (n = 13) and the origin of nine (7.9%) isolates could not be determined.

Identification and antimicrobial susceptibility testing

The isolates were previously identified using VITEK-2 automated system (BioMerieux, Craponne, France) as A. baumannii-A. calcoaceticus complex at the microbiology laboratories of each of the two health institutions. The final identification of A. baumannii-A. calcoaceticus complex was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry on a Maldi Biotyper platform (Bruker Daltonics, Germany).

The disc diffusion method was used to evaluate susceptibility to the following antimicrobials agents according to Clinical and Laboratory Standards Institute guidelines10: amikacin (30 μg), ampicillin/sulbactam (10/10 μg), ceftazidime (30 μg), cefepime (30 μg), ciprofloxacin (5 μg), gentamicin (10 μg), imipenem (10 μg), meropenem (10 μg), sulfamethoxazole/trimethoprim (23.75 μg/1.25 μg), tetracycline (30 μg), and tobramycin (10 μg). Minimum inhibitory concentration (MIC) values for imipenem (23.75 μg/1.25 μg), amikacin (30 μg), ciprofloxacin (90%), gentamicin (100%), meropenem (92%). The highest rates of susceptibility were observed with amikacin (3/114; 2.6%) and tetracycline (4/114; 3.5%) in both hospitals. In general, the resistance rates verified in Hospital 2 were higher than those in Hospital 1, except for trimethoprim/sulfamethoxazole and tobramycin. In addition, given the number of carbapenem-resistant isolates from both hospitals, 82.1% isolates were resistant to at least one agent of two more other classes of antimicrobials tested, indicating multidrug resistance.

According to the PCR results, 96.5% (110/114) of isolates presented blaOXA-51-like, originally intrinsic to A. baumannii, and 95.6% (109/114) carried blaOXA-23-like. No isolate was positive for the other OXA-encoding genes investigated.

All 109 blaOXA-23-like, blaOXA-51-like-positive isolates were resistant to at least one of the carbapenem tested, except for one isolate (from Hospital 1) that had an imipenem MIC of 0.38 μg/mL. One isolate positive to only blaOXA-51-like (from Hospital 2) was resistant to 9 of 11 antibiotics tested including the two carbapenems tested, and was susceptible to only tetracycline and ceftazidime.

PFGE analysis of the 25 isolates from Hospital 1 revealed a polyclonal pattern, but with three major genotypes: A (n = 5; 20%), C (n = 4; 16%), and D (n = 4; 16%). The five isolates belonging to genotype A clustered with four genotype A representative strains, detected in a previous study, with a coefficient of similarity of ≥ 80%. None of the analyzed isolates was related to the three representative strains belonging to genotype B. (Table 1).

For Hospital 2, one predominant genotype, named N, included six isolates (46.2%), clustered with 80% similarity

---

Oliveira EA et al. - OXA-23-producing Acinetobacter
TABLE 1: Characteristics of 38 OXA-23-producing *Acinetobacter* isolated in Niterói city, Brazil.

| Pulsotype | Isolate | Hospital | Date of Isolation | Clinical specimen | Antimicrobial resistance profile* |
|-----------|---------|---------|-------------------|-------------------|-----------------------------------|
| A         | CS30122 | 1       | 04/30/13          | Blood             | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30134 | 1       | 05/14/13          | Urine             | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30151 | 1       | 05/24/13          | Liquor            | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30153 | 1       | 05/26/13          | Liquor            | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30246 | 1       | 09/02/13          | Blood             | IMP; MER; CPM; SUT |
| C         | CS30105 | 1       | 03/25/13          | Catheter tip      | IMP; MER; GEN; CIP; SUT |
|           | CS30115 | 1       | 04/19/13          | Catheter tip      | IMP; MER; CIP; SUT |
|           | CS30121 | 1       | 05/01/13          | Blood             | IMP; MER; GEN; TOB; CIP; SUT |
|           | CS30176 | 1       | 06/20/13          | Urine             | IMP; MER; CPM; SUT |
| D         | CS30279 | 1       | 10/01/13          | BALb              | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30265 | 1       | 10/07/13          | Blood             | IMP; MER; CPM; GEN; TOB; CIP; SUT |
|           | CS30289 | 1       | 11/01/13          | Blood             | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30292 | 1       | 11/02/13          | Blood             | IMP; MER; CIP; SUT |
| E         | CS30321 | 1       | 11/08/13          | Urine             | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30322 | 1       | 11/23/13          | Blood             | IMP; MER; CAZ; CIP; SUT |
| F         | CS30118 | 1       | 04/19/13          | Tracheal secretion| IMP; MER; CAZ; CIP |
| G         | CS30278 | 1       | 09/30/13          | Blood             | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30282 | 1       | 09/19/13          | Skin biopsy       | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
| H         | CS30280 | 1       | 09/30/13          | Urine             | IMP; MER; CIP |
|           | CS30283 | 1       | 09/30/13          | Blood             | IMP; MER; CIP |
| I         | CS30204 | 1       | 07/09/13          | Blood             | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
| J         | CS30177 | 1       | 06/21/13          | Catheter tip      | IMP; MER; CPM; SUT; CIP |
| K         | CS30323 | 1       | 12/13/13          | Urine             | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
| L         | CS30284 | 1       | 10/14/13          | Blood             | IMP; MER; CPM; SUT |
| M         | CS30174 | 1       | 06/07/13          | Renal perfusion fluid | none |
| N         | CS30104 | 2       | 03/25/13          | Catheter tip      | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30162 | 2       | 05/25/13          | Blood             | IMP; MER; CIP; SUT |
|           | CS30199 | 2       | 07/04/13          | Abdominal fragment| IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30195 | 2       | 07/29/13          | BAL               | IMP; MER; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30213 | 2       | 07/30/13          | Blood             | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
|           | CS30214 | 2       | 07/30/13          | BAL               | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP; SUT |
| O         | CS30111 | 2       | 05/20/13          | BAL               | IMP; MER; ASB; CAZ; CPM; GEN; TOB; CIP |
| P         | CS30182 | 2       | 06/01/13          | Catheter tip      | IMP; MER; CAZ; CPM; GEN; CIP |
| Q         | CS30197 | 2       | 07/15/13          | BAL               | IMP; MER; CAZ; GEN; TOB; CIP; SUT |
| R         | CS30254 | 2       | 09/09/13          | Tracheal secretion| IMP; MER; ASB; CAZ; CPM; GEN; CIP |
| S         | CS30258 | 2       | 09/13/13          | Rectal swab       | IMP; MER; CIP |
| T         | CS30136 | 2       | 04/29/13          | Pleural fluid     | IMP; MER; CAZ; CPM; CIP |
| U         | CS30198 | 2       | 07/02/13          | Catheter tip      | IMP; MER; CIP |

*IMP: Imipenem, MER: Meropenem, ASB: Ampicillin/Sulbactam, CAZ: Ceftazidime, CPM: Cefepime, GEN: Gentamicin, TOB: Tobramycin, CIP: Ciprofloxacin, SUT: Sulfamethoxazole/Trimethoprim; b: BAL: Bronchoalveolar lavage.

(Table 1). Inter-hospital dissemination was not observed in our study.

**DISCUSSION**

This study described the resistance profiles and genetic relatedness of carbapenem-resistant *A. baumannii* complex isolates collected from patients in two health institutions located in Niterói, Rio de Janeiro, Brazil.

Carbapenem resistance is a serious problem in the treatment of infections caused by *Acinetobacter*, since these antibiotics are considered as one of the best therapeutic options for the treatment of severe infections caused by *Acinetobacter*. A study from SENTRY showed an increase in the proportion of carbapenem-resistant *Acinetobacter* spp., with the rate of 70% in 2008-2009. Another study from Niterói also verified carbapenem-resistance rate of 70% among *Acinetobacter* isolated in 2007-2009. In the present study, an even higher resistance rate to carbapenems was observed (> 90%) comparable to the results of other recent Brazilian studies that also showed carbapenem resistance rate > 90% among *A. baumannii* isolates, highlighting an increasing trend in the dissemination of carbapenem-resistant *Acinetobacter* isolates in the last few years.

We noted that carbapenem resistance was mediated by the enzyme OXA-23 in most isolates. These results are in agreement with the literature, which reported the spread of
OXA-23-producing *Acinetobacter* strains in various locations worldwide and the predominance of this OXA in Brazilian territories, being directly responsible for the high rates of carbapenem resistance. The relationship between OXA-23 production and imipenem-resistance ratio among the isolates in both hospitals was also observed. The isolates positive for bla\(_{OXA-23}\) were also resistant to imipenem, except one isolate.

Furthermore, the high prevalence of bla\(_{OXA-51}\) positive isolates detected in this study showed that *A. baumannii* was the most frequent species, since the oxacillinase is intrinsic in this species. It is noteworthy that, although some studies have described the occurrence of bla\(_{OXA-51}\) in *A. nosocomialis*, this still appears to be a rare event.

A carbapenem-resistant isolate was positive only for bla\(_{OXA-51}\). The reduced susceptibility to carbapenems in this non-OXA-23 isolates may be mediated by bla\(_{OXA-51}\) overexpression due to the association with the IS element. One carbapenem-susceptible isolate was positive for bla\(_{OXA-22}\) and bla\(_{OXA-51}\). This result may be explained by the absence of IS element upstream in the bla\(_{OXA-23}\)-like. However, susceptible carbapenem isolates carrying bla\(_{OXA-23}\) are considered as silent reservoirs of this gene and can be the source of their spread in a nosocomial environment.

In this study, bla\(_{OXA-21}\) genes other than bla\(_{OXA-22}\) and bla\(_{OXA-51}\) were not found, but a bla\(_{OXA-72}\)-positive *Acinetobacter* clinical isolate was obtained for the first time from a public hospital in Niterói, Rio de Janeiro. The increasing occurrence of OXA-72-positive *Acinetobacter* isolates in Brazil and OXA-143-producing isolates highlights the importance of continuous epidemiological surveillance to help prevent the dissemination of these organisms.

A wide variety of clonal lineages of bla\(_{OXA-23}\) *A. baumannii* isolates causing hospital outbreaks has been reported in various studies in Brazil. In this study, genotype A that was detected previously was observed in 5 of the 25 OXA-23-positive strains from Hospital 1 analyzed by PFGE. These results indicate that this strain circulates in the hospital. Some of the OXA-23-producing clones disseminated in Brazil as the clones belonging to ST79 persist and disseminate in the hospital environment.

In this study, we did not perform Multilocus Sequence Type MLST analysis of the OXA-23-positive isolates; therefore, our conclusions about these results obtained are limited.

Among the 13 OXA-23-positive isolates from Hospital 2 that was analyzed by PFGE, a multidrug-resistant predominant genotype (N) was detected, which included 46.2% of the isolates. This result suggests that the intra-hospital spread of this particular clonal group may have contributed to the high rate of carbapenem resistance observed in this institution.

Isolates with unique profiles were detected in both hospitals, indicating that in addition to clonal spread, bla\(_{OXA-23}\) was also acquired through horizontal spread in the investigated population. Studies have shown that the dissemination of carbapenemase-producing isolates appears to be due to clonal dissemination; however, studies have also highlighted the horizontal spread of bla\(_{OXA-23}\).

In conclusion, carbapenem resistance mediated by OXA-23 was high, with most isolates being resistant to carbapenems. A high genetic diversity was verified among the OXA-23-positive isolates analyzed, with the occurrence of both clonal and horizontal dissemination of bla\(_{OXA-23}\)-like. These results suggest a need for continuous epidemiological surveillance studies to assist in the control of dissemination of these carbapenem-resistant strains in the investigated hospitals.

**ACKNOWLEDGEMENTS**

We thank Dr. Lucia Martins Teixeira (Instituto de Microbiologia Paulo de Góes/UFRJ) and her group for the help with BioNumerics PFGE analysis and MALDI-TOF identification of the isolates.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**Financial Support**

Pro-rectory of Research, Postgraduate and Innovation / Fluminense Federal University.

**REFERENCES**

1. Medeiros M, Linconop N. Oxacillinase (OXA)-producing *Acinetobacter baumannii* in Brazil: clinical and environmental impact and therapeutic options. J Bras Patol Med Lab. 2013;49(6):391-405.

2. Lin MF, Lan CY. Antimicrobial resistance in *Acinetobacter baumannii*: from bench to bedside. World J Clin Cases. 2014;2(12):787-814.

3. Gordon NC, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35(3):219-26.

4. Pillonetto M, Arend L, Vespero EC, Pelisson M, Chagas TP, Carvalho-Assef AP, et al. First report of NDM-1-producing *Acinetobacter baumannii* sequence type 25 in Brazil. Antimicrob Agents Chemother. 2014;58(12):7592-4.

5. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, Léon CF, et al. Detection of KPC in *Acinetobacter* spp. in Puerto Rico. Antimicrob Agents Chemother. 2010;54(3):1354-7.

6. Pawel N, Paulina P. *Acinetobacter baumannii*: biology and drug resistance — role of carbapenemases. Folia Histochim Cytobiol. 2016;54:61-74.

7. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. Antimicrob Agents Chemother. 2013;57(5):2121-6.

8. Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis. 2011;52(9):1138-43.

9. Antonio CS, Neves PR, Medeiros M. High Prevalence of carbapenem-resistant *Acinetobacter baumannii* carrying the bla\(_{OXA-14}\) gene in Brazilian Hospitals. Antimicrob Agents Chemother. 2011;55(3):1322-3.

10. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2018.

11. Schuenck RP, Pereira EM, Iorio NL. Multiplex PCR assay to identify methicillin-resistant *Staphylococcus haemolyticus*. FEMS Immunol Med Microbiol. 2008;52(3):431-5.
12. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Inter J Antimicrob Agents. 2006;27(4):351-3.

13. Higgins PG, Poirel LM. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009;53(12):5035-8.

14. Gauton R. Rapid Pulsed-Field Gel Electrophoresis Protocol for Typing of Escherichia coli O157:H7 and Other Gram-Negative Organisms in 1 Day. J Clin Microbiol. 1997;35(11):2977-80.

15. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram Negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis. 2012;73(4):354-60.

16. Corrêa LL, Botelho LA, Barbosa LC, Mattos CS, Carballido JM, Castro CL T, et al. Detection of blaOXA-23 in Acinetobacter spp. isolated from patients of a university hospital. Braz J Infect Dis. 2012;16(6):521-6.

17. De Azevedo FKSF, Dutra V, Nakazato L, Mello CM, Pepato MA, Sousa ATH, et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii infection in two hospitals in Central Brazil: the role of ST730 and ST 162 in clinical outcomes. J Med Microbiol. 2019;68(1):31-40.

18. Vasconcelos AT, Barth AL, Zavascki AP, Gales AC, Levin AS, Lucarevski BR, et al. The changing epidemiology of Acinetobacter spp producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report. Diagn Microbiol Infect Dis. 2015;83(4):382-5.

19. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35-40.

20. Chagas TP, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef AP, Asensi MD. Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79). Diagn Microbiol Infect Dis. 2014;79(4):468-72.

21. Martins AF, Kuchenbecker R, Sukienik T. Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme: dissemination in Southern Brazil. Infection. 2009;37(5):474-6.

22. Lee T, Kuo SC, Chiang MC. Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-23 like gene that is intrinsic to A. baumannii. Antimicrob Agents Chemother. 2012;56(2):1124-7.

23. Pagano M, Martins AF, Barth AL. Mobile genetic elements related to carbapenem resistance in Acinetobacter baumannii. Brazil J Microbiol. 2016;47(4):785-92.

24. Poirel SLF, Papa A, Koulourida V, Carvalho KR, Carvalho-Assef AP, Santos LG, et al. Occurrence of blaOXA-23 gene in imipenem-susceptible Acinetobacter baumannii. Mem Inst Oswaldo Cruz. 2011;106(4):505-6.

25. Paweł N, Paulina P. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases. Folia Histochem Cytobiol. 2016;54(2):61-74.

26. Carvalho KR, Carvalho-Assef AP, Santos LG, Pereira MJ, Asensi MD. Occurrence of blaOXA-23 gene in imipenem-susceptible Acinetobacter baumannii. Mem Inst Oswaldo Cruz. 2011;106(4):505-6.

27. Dalla-Costa LM, Coelho JM, Souza HA. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol. 2003;41(7):3403-6.

28. Pagano M, Nunes LS, Niada M, Barth AL, Martins AF. Comparative analysis of carbapenem-resistant Acinetobacter baumannii sequence types in Southern Brazil: from the first outbreak (2007-2008) to the endemic period (2013-2014). Microb Drug Resist. 2019;25(4):538-42.

29. Valenzuela JK, Thomas L, Partridge SR. Horizontal gene transfer in a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii. J Clin Microbiol. 2007;45(2):453-60.

30. Karah N, Sundsfjord A, Towner K. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resistant Updat. 2012;15(4):237-47.